Acute Promyelocytic Leukemia: Pathophysiology, Laboratory and Clinical Characteristics, Treatment and Minimal Residual Disease- A Literature Review
- Acute promyelocytic leukemia,
- Minimal residual disease
Copyright (c) 2019 Amorin
This work is licensed under a Creative Commons Attribution 4.0 International License.
Acute Promyelocytic Leukemia (APL) is a subtype of acute leukemia characterized by a predominance of cells with characteristic morphology, by t(15;17) and coagulopathy. It is designated as M3 by FAB classification and as APL with t(15;17) or PML/RARα rearrangement by the World Health Organization. Unlike other subtypes of acute myeloid leukemia (AML), APL occurs most often in young adults and has a stable incidence between 20 to 59 years old. This disease, which used to be highly mortal, has become a curable disease since the establishment of standard treatment with all-trans retinoic acid and anthracyclines in the 90s. Therefore, this study aimed to review the pathophysiology, diagnosis, prognosis, treatment, and monitoring response to treatment of APL.